Results 111 to 120 of about 168,682 (384)

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan, María A. Piedrabuena, María A. Zarate, Sofía Rodríguez Murúa, Ezequiel I. Surace, Mauricio F. Farez, Marcela P. Fiol, María C. Ysrraelit, Jorge Correale   +8 more
wiley   +1 more source

Response to: Monoclonal antibodies targeting CD20 [PDF]

mAbs, 2013
Dear Editor, Please allow us to briefly reply to the comments by Dr. Goldenberg and colleagues. As stated in the disclosures, some authors are employees of Roche Glycart AG or Roche Diagnostics GmbH and have contributed to the (non-) clinical development of the glycoengineered Type II CD20 antibody GA101 (obinutuzumab).
Wolfgang Schäfer, Pablo Umana, Christian Klein, Gerhard Niederfellner, Alfred Lammens, Manfred Schwaiger, Karl-Peter Hopfner, Guy Georges, Ekkehard Mössner   +8 more
openaire   +3 more sources

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies

Oncotarget, 2016
Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies.
Jahn, L., Steen, D.M. van der, Hagedoorn, R.S., Hombrink, P., Kester, M.G.D., Schoonakker, M.P., Ridder, D. de, Veelen, P.A. van, Falkenburg, J.H.F., Heemskerk, M.H.M.   +9 more
openaire   +5 more sources

Anti-CD20: tales of identical twins? [PDF]

Blood, 2011
In this issue of Blood , Wierda et al show in a retrospective analysis of 206 patients that prior rituximab exposure does not affect the efficacy of subsequent ofatumumab treatment.[1][1] Although these results will have to be confirmed prospectively, they begin to unravel clinically ...
openaire   +4 more sources

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis

Scientific Reports, 2020
Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20+ B-NHL). Recently new anti-CD20 monoclonal antibodies (mAbs) have been developed, but their efficacy and safety compared with ...
Chengxin Luo, Guixian Wu, Xiang-tao Huang, Ya-Feng Ma, Yali Zhang, Qiuyue Song, Ming-ling Xie, Yanni Sun, Yarui Huang, Zhen Huang, Yu Hou, Shuangnian Xu, Jieping Chen, Xi Li   +13 more
semanticscholar   +1 more source

Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist during Treatment with Rituximab

Clinical Medicine Insights: Oncology, 2008
Potential progenitor B cell compartments in multiple myeloma (MM) are clinically important. MM B cells and some circulating MM plasma cells express CD20, predicting their clearance by treatment with anti-CD20.
Linda M. Pilarski, Eva Baigorri, Michael J. Mant, Patrick M. Pilarski, Penelope Adamson, Heddy Zola, Andrew R. Belch   +6 more
doaj   +1 more source

Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies

FEBS Letters, EarlyView.
Daniel Bachurski, Michael Hallek
wiley   +1 more source

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesca Caputo, Marta Simone, Massimiliano Copetti, Damiano Paolicelli, Emilio Portaccio, Francesco Patti, Paola Perini, Vincenzo Brescia Morra, Alessia Di Sapio, Matilde Inglese, Carlo Pozzilli, Giacomo Lus, Giuseppe Salemi, Erica Curti, Giovanna De Luca, Paola Valentino, Eleonora Cocco, Paola Cavalla, Carlo Avolio, Alessandra Lugaresi, Antonio Gallo, Pietro Annovazzi, Maria A. Rocca, Clara Grazia Chisari, Massimo Filippi, Maria Pia Amato, Maria Trojano, on behalf of the Italian MS Register, Beatrice Biolzi, Daniele Dell’Anna, Daniele Di Giulio Cesare, Sonia Di Lemme, Chiara Di Tillio, Teresa Fonsdituri, Ilaria Maietta, Agata Marchese, Silvia Marinetto, Federica Martini, Cristiana Morano, Silvia Perugini, Giovanna Ramona Piredda, Chiara Raimondi, Ilaria Rossi, Valentina Tallarico, Stefania Treccarichi   +47 more
wiley   +1 more source